As a leader in heart valves for over 60 years, Edwards Lifesciences is dedicated to providing you a destination for the latest transcatheter heart valve information, tools, resources, and innovative solutions.

The SAPIEN 3 Ultra valve, powered by RESILIA tissue technology

SAPIEN 3 Ultra RESILIA valve takes TAVI even further with the potential to improve valve longevity and reduce reintervention. *† Building on the benefits of the SAPIEN 3 platform, the SAPIEN 3 Ultra RESILIA valve also includes the feature of our RESILIA tissue, our proprietary calcium-blocking technology. RESILIA tissue is the same tissue technology used in the #1 implanted surgical valve in the US, and is the only transcatheter heart valve (THV) with dry tissue storage.

Learn about SAPIEN 3 Ultra RESILIA valve

*No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.
RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards Lifesciences in a juvenile sheep model. Flameng W, et al. J Thorac Cardiovasc Surg. 2015;149 (1):340-345.

ACC/AHA Guideline expands TAVI as a Class I recommendation

The ACC/AHA released key updates in their 2020 Guideline for Valvular Heart Disease, including recommendations for the treatment of severe symptomatic aortic stenosis and transcatheter valve repair/implantation for patients. Have these guidelines readily available for your team.

Research and education grants

Through its educational and research grant programs, Edwards Lifesciences is committed to supporting independent programs that further clinical knowledge, scientific exchange, medical education and delivery of effective therapies for structural heart disease and critical care monitoring, and is further committed to supporting independent research in the area of valve science and hemodynamic monitoring in order to enhance scientific knowledge for the purpose of extending and enhancing human life.

Go to the Edwards Lifesciences Grant portal

Stay connected

Be the first to receive the latest news in transcatheter heart valves, including event announcements.

References:   1. De Backer O, Landes U, Fuchs A, et al. Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography. JACC Cardiovasc Interv. 2020; 13(21):2528-2538.